China Tobacco International (HK) Reports Strong Growth in 2023

Business by 2FIRSTS Leona Zhu, edited by Sophia
Mar.20.2024
China Tobacco International (HK) Reports Strong Growth in 2023
China Tobacco (HK) releases 2023 annual report performance highlights, showing growth in new tobacco sector. 2FIRSTS examines key points.

In March 2024, China Tobacco (Hong Kong) released its annual performance report for 2023, detailing the overall performance for the year and highlighting key indicators for the new tobacco sector over the past year. 2FIRSTS conducted a review of the highlights of the annual report.

 

Steady Progress in New Tobacco Business Sector

 

China Tobacco International (HK) began exporting new tobacco products in May 2018, primarily targeting the Asian market, such as South Korea. These new tobacco products include HNB tobacco products. In 2023, the sales revenue of China Tobacco International (HK) from new tobacco products reached 129,979 million Hong Kong dollars, accounting for 1% of the group's total annual revenue of 11,836,221 million Hong Kong dollars in 2023, an 18% increase from the new tobacco sales revenue of 110,133 million Hong Kong dollars in 2022.

 

However, it is worth noting that the overall proportion of the new tobacco sector in 2022 was 1.3%. In other words, in the past year, the proportion of new tobacco in China Tobacco International (HK) business has slightly decreased on a basis of basically holding steady. At the same time, even though the gross profit margin of the new tobacco sector has increased (4.4%) compared to before, it still lags behind core business sectors such as the cigarette export business sector with a gross profit margin of 13.57%.

 

The decline in numbers does not mean a neglect of novel tobacco products. Since its listing in Hong Kong in 2019, China Tobacco International (HK) has been consistently exporting novel tobacco products to global markets for five years. This is still highlighted in the 2023 annual report, showcasing the company's continued focus on this sector.

 

Gaining Momentum to Catch up with 3 Major Giants

 

At the same time, when compared with its industry peers, China Tobacco International (HK) is also showing strong growth momentum in its new tobacco products.

 

In 2023, the export quantity of China Tobacco International (HK) new tobacco products was 677,310 thousand units, an increase of 174,920 thousand units, representing a growth of 35% compared to the previous year. The operating income was 130.0 million Hong Kong dollars, an increase of 19.8 million Hong Kong dollars, representing an 18% growth. The gross profit was 5.7 million Hong Kong dollars, an increase of 2.5 million Hong Kong dollars, representing an 80% growth compared to the previous year.

 

China Tobacco International (HK) attributed its performance growth in the annual report to the following three factors:

 

Firstly, due to an increase in order demand. Over the past year, China Tobacco International (HK) has intensified efforts to expand international market channels and customers, seizing opportunities in emerging markets and deepening expansion in key markets.

 

The second reason is that the product has strong competitiveness. In the past year, China Tobacco International (HK) has strengthened the coordination of production, supply, and marketing. It has developed competitive products in response to changing market demand.

 

The third point is the increase in profit margin. A rich product portfolio and ongoing optimization of business structures have driven the increase in profit margin.

 

China Tobacco International (HK) Reports Strong Growth in 2023

 

A comparison of the annual reports of the other three major tobacco companies reveals that China Tobacco International (HK) may not match the absolute export quantities of its competitors (PMI 125.2 billion, BAT 29.7 billion, and JTI 8.8 billion), but it surpasses the closest competitor JT by more than two billion. Additionally, its 35% increase in shipment volume is three times higher than the highest of the three, PMI at 11.8%. Furthermore, its growth in revenue and gross profit is significantly ahead as well.

 

Compliance Expansion Goal for Promising Future

 

In addition to new tobacco products, including traditional cigarettes and other service businesses, China Tobacco International (HK) as a whole also achieved excellent results. In 2023, China Tobacco International (HK) achieved a revenue of HK$11.836 billion, an increase of 42.19% year-on-year; achieved a gross profit of HK$1.088 billion, an increase of 34.96% year-on-year; and achieved a net profit of HK$599 million attributable to equity holders of the company, a significant increase of 59.72% year-on-year, exceeding previous profit forecast expectations.

 

When discussing the future development strategy of the export business of new tobacco products, China Tobacco International (HK) has clearly outlined several directions: strengthening monitoring of international market dynamics and demand research, focusing on key market expansion and accelerating the development of new markets, continuously promoting product upgrade iteration, optimizing supply chain models, improving market response capabilities, and expanding the scale of sales of new tobacco products.

 

Meanwhile, China Tobacco International (HK) emphasized the importance of "strengthening the protection of their own brand intellectual property rights." This may indicate that the group will launch more new tobacco brands in the future, which is worth keeping an eye on in the industry.

 

Similarly, in terms of corporate social responsibility, China Tobacco International (HK) emphasized the strengthening of its volunteer team, organizing activities such as community visits, tree planting, and coastal clean-ups to establish a positive external image. This also demonstrates the group's focus on local compliance and its commitment to further accelerate its overseas expansion in the future.

 

2FIRSTS will continue to monitor the international expansion of China Tobacco International (HK) and its new tobacco sector.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
British American Tobacco Japan (BAT Japan) expanded VELO Peach Ice Medium to FamilyMart stores nationwide in Japan from September 7, 2026. The oral tobacco product first launched on July 6 and had previously been sold through VELO's official online store, glo Store Ginza and tobacco retailers. It combines peach flavor with menthol cooling at a Medium strength level and is priced at JPY 360. Japanese tobacco retailers list 15 pouches per pack. The move adds the new SKU to an existing nationwide FamilyMart distribution network for VELO rather than marking the brand's first entry into the convenience-store chain.
Sep.15
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29